Scientists have uncovered new details about how pancreatic cancer cells alter their genetic characteristics as the disease develops, potentially helping them spread and resist treatment. The findings could open new avenues for research into therapies that target the mechanisms driving the cancer’s aggressive behaviour.
The research focused on pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer and one of the most challenging cancers to treat. By analysing individual tumour cells, researchers gained a more detailed understanding of how different groups of cancer cells behave within the same tumour.
How Cancer Cells Adapt and Become More Aggressive
The research team examined 443,451 individual cells collected from 62 tumours belonging to 56 patients. The analysis revealed that pancreatic tumours can contain several distinct groups of cancer cells, known as clones, which may behave differently as the disease progresses.
Some cell groups developed characteristics associated with resistance to treatment, while others showed features linked to invasion and the spread of cancer to other parts of the body. These differences suggest that pancreatic cancer can evolve within an individual tumour rather than remaining biologically uniform.
The researchers also investigated how cancer cells shift between two broad states: the classical type, generally considered less aggressive, and the basal type, associated with more aggressive behaviour.
MYC Gene Emerges as a Potential Treatment Target
One important finding involved MYC, a gene that was more active in some aggressive cancer-cell populations. In laboratory experiments, blocking MYC activity caused certain aggressive cells to shift towards a less aggressive state.
The change also made these cells more exposed to immune cells, raising the possibility that altering this pathway could help the immune system recognise cancer more effectively.
However, the experiments were conducted in laboratory settings. Further research is needed to establish whether targeting MYC can safely and effectively improve outcomes for patients.
Why Pancreatic Cancer Can Evade the Immune System
The study also identified differences in the activity of genes associated with immune evasion, including TIGIT and PD1. Certain cancer-cell populations showed higher TIGIT activity and lower PD1 activity, offering a possible explanation for why some immunotherapies have had limited effectiveness against pancreatic cancer.
Understanding these differences could help researchers investigate more targeted treatment strategies based on the biological characteristics of individual tumours.
What the Findings Mean for Future Treatment
The study provides a closer look at how pancreatic cancer develops, changes and potentially escapes treatment. By identifying the genetic mechanisms involved, scientists hope to find new ways to limit tumour progression and improve treatment options.
The findings are an important research step, but they do not represent a proven new treatment. Clinical studies will be needed to determine whether these discoveries can translate into meaningful benefits for people living with pancreatic cancer.
